Metropolitan Life Insurance CO Geron Corp Transaction History

Metropolitan Life Insurance CO

$281 Million
Q3 2024

60 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$1.75 - $3.44 $3,601 - $7,079	-2,058 Reduced 8.06%	23,482 $77,000
Q4 2023 Feb 14, 2024	SELL	$1.74 - $2.31 $5,585 - $7,415	-3,210 Reduced 11.17%	25,540 $53,000
Q3 2023 Nov 14, 2023	BUY	$2.11 - $3.28 $3,230 - $5,021	1,531 Added 5.62%	28,750 $60,000
Q2 2023 Aug 10, 2023	BUY	$1.97 - $3.69 $7,986 - $14,959	4,054 Added 17.5%	27,219 $87,000
Q1 2023 May 15, 2023	BUY	$2.14 - $3.4 $1,855 - $2,947	867 Added 3.89%	23,165 $50,000
Q4 2022 Jun 14, 2023	SELL	$2.03 - $2.42 $1,760 - $2,098	-867 Reduced 3.74%	22,298 $54 Million
Q4 2022 Mar 30, 2023	BUY	$2.03 - $2.42 $8,741 - $10,420	4,306 Added 23.93%	22,298 $53,000
Q4 2022 Feb 15, 2023	BUY	$2.03 - $2.42 $8,741 - $10,420	4,306 Added 23.93%	22,298 $53,000
Q3 2022 Jun 14, 2023	SELL	$1.67 - $2.94 $8,638 - $15,208	-5,173 Reduced 22.33%	17,992 $42.1 Million
Q3 2022 Mar 30, 2023	SELL	$1.67 - $2.94 $6,619 - $11,654	-3,964 Reduced 18.05%	17,992 $42,000
Q3 2022 Nov 14, 2022	SELL	$1.67 - $2.94 $6,619 - $11,654	-3,964 Reduced 18.05%	17,992 $42,000
Q2 2022 Jun 20, 2023	SELL	$1.19 - $1.65 $1,438 - $1,994	-1,209 Reduced 5.22%	21,956 $34,000
Q2 2022 Mar 30, 2023	BUY	$1.19 - $1.65 $14,660 - $20,328	12,320 Added 127.85%	21,956 $34,000
Q2 2022 Aug 11, 2022	BUY	$1.19 - $1.65 $14,660 - $20,328	12,320 Added 127.85%	21,956 $34,000
Q1 2022 Jun 20, 2023	SELL	$0.99 - $1.6 $13,393 - $21,646	-13,529 Reduced 58.4%	9,636 $13,000
Q1 2022 Mar 30, 2023	SELL	$0.99 - $1.6 $74,914 - $121,073	-75,671 Reduced 88.7%	9,636 $13,000
Q1 2022 May 12, 2022	SELL	$0.99 - $1.6 $74,914 - $121,073	-75,671 Reduced 88.7%	9,636 $13,000
Q4 2021 Jun 21, 2023	BUY	$1.22 - $1.72 $75,813 - $106,884	62,142 Added 268.26%	85,307 $104,000
Q4 2021 Mar 30, 2023	BUY	$1.22 - $1.72 $18,975 - $26,752	15,554 Added 22.3%	85,307 $104,000
Q4 2021 Feb 15, 2022	BUY	$1.22 - $1.72 $18,975 - $26,752	15,554 Added 22.3%	85,307 $104,000
Q3 2021 Jun 21, 2023	BUY	$1.2 - $1.5 $55,905 - $69,882	46,588 Added 201.11%	69,753 $95,000
Q3 2021 Mar 30, 2023	BUY	$1.2 - $1.5 $33,546 - $41,932	27,955 Added 66.88%	69,753 $95,000
Q3 2021 Nov 15, 2021	BUY	$1.2 - $1.5 $33,546 - $41,932	27,955 Added 66.88%	69,753 $96,000
Q2 2021 Jun 21, 2023	BUY	$1.25 - $1.83 $23,291 - $34,098	18,633 Added 80.44%	41,798 $58,000
Q2 2021 Mar 30, 2023	SELL	$1.25 - $1.83 $46,722 - $68,401	-37,378 Reduced 47.21%	41,798 $58,000
Q2 2021 Aug 16, 2021	BUY	$1.25 - $1.83 $52,148 - $76,345	41,719 Added 52808.86%	41,798 $59,000
Q1 2021 Jun 26, 2023	BUY	$1.52 - $2.1 $85,136 - $117,623	56,011 Added 241.79%	79,176 $125 Million
Q1 2021 Mar 30, 2023	SELL	$1.52 - $2.1 $1,348 - $1,862	-887 Reduced 1.11%	79,176 $125,000
Q1 2021 May 14, 2021	SELL	$1.52 - $2.1 $121,575 - $167,966	-79,984 Reduced 99.9%	79 $125,000
Q4 2020 Jun 22, 2023	BUY	$1.55 - $2.05 $88,191 - $116,640	56,898 Added 245.62%	80,063 $127,000
Q4 2020 Mar 30, 2023	SELL	$1.55 - $2.05 $14,455 - $19,118	-9,326 Reduced 10.43%	80,063 $127,000
Q4 2020 Feb 16, 2021	SELL	$1.55 - $2.05 $14,455 - $19,118	-9,326 Reduced 10.43%	80,063 $127,000
Q3 2020 Jun 26, 2023	BUY	$1.59 - $2.19 $105,296 - $145,030	66,224 Added 285.88%	89,389 $155,000
Q3 2020 Mar 30, 2023	BUY	$1.59 - $2.19 $39,088 - $53,838	24,584 Added 37.94%	89,389 $155,000
Q3 2020 Nov 13, 2020	BUY	$1.59 - $2.19 $39,088 - $53,838	24,584 Added 37.94%	89,389 $156,000
Q2 2020 Jun 26, 2023	BUY	$1.05 - $2.18 $43,722 - $90,775	41,640 Added 179.75%	64,805 $141,000
Q2 2020 Mar 30, 2023	SELL	$1.05 - $2.18 $1,122 - $2,330	-1,069 Reduced 1.62%	64,805 $141,000
Q2 2020 Aug 14, 2020	SELL	$1.05 - $2.18 $1,122 - $2,330	-1,069 Reduced 1.62%	64,805 $141,000
Q1 2020 Jul 12, 2023	BUY	$0.89 - $1.49 $38,011 - $63,636	42,709 Added 184.37%	65,874 $78,000
Q1 2020 Mar 30, 2023	SELL	$0.89 - $1.49 $2,446 - $4,096	-2,749 Reduced 4.01%	65,874 $78,000
Q1 2020 May 15, 2020	SELL	$0.89 - $1.49 $2,446 - $4,096	-2,749 Reduced 4.01%	65,874 $78,000
Q4 2019 Jul 12, 2023	BUY	$1.27 - $1.54 $57,731 - $70,005	45,458 Added 196.24%	68,623 $93,000
Q4 2019 Mar 30, 2023	BUY	$1.27 - $1.54 $50,953 - $61,786	40,121 Added 140.77%	68,623 $93,000
Q4 2019 Feb 14, 2020	BUY	$1.27 - $1.54 $50,953 - $61,786	40,121 Added 140.77%	68,623 $93,000
Q3 2019 Jul 12, 2023	BUY	$1.15 - $1.59 $6,137 - $8,485	5,337 Added 23.04%	28,502 $37,000
Q3 2019 Mar 30, 2023	SELL	$1.15 - $1.59 $42,271 - $58,445	-36,758 Reduced 56.33%	28,502 $37,000
Q3 2019 Nov 14, 2019	SELL	$1.15 - $1.59 $42,271 - $58,445	-36,758 Reduced 56.33%	28,502 $38,000
Q2 2019 Jul 12, 2023	BUY	$1.37 - $2.02 $57,670 - $85,031	42,095 Added 181.72%	65,260 $92,000
Q1 2019 Jul 13, 2023	BUY	$1.01 - $1.83 $42,515 - $77,033	42,095 Added 181.72%	65,260 $108,000
Q1 2019 Mar 30, 2023	BUY	$1.01 - $1.83 $43,391 - $78,620	42,962 Added 192.67%	65,260 $108,000
Q1 2019 May 16, 2019	SELL	$1.01 - $1.83 $392,074 - $710,393	-388,193 Reduced 85.61%	65,260 $108,000
Q1 2019 May 15, 2019	BUY	$1.01 - $1.83 $457,987 - $829,818	453,453 New	453,453 $18.1 Million
Q4 2018 Feb 14, 2019	SELL	$0.98 - $1.85 $10,722 - $20,240	-10,941 Closed	0 $0
Q3 2018 Jul 13, 2023	BUY	$1.76 - $6.38 $48,074 - $174,269	27,315 Added 117.91%	50,480 $88.8 Million
Q3 2018 Nov 14, 2018	SELL	$1.76 - $6.38 $69,588 - $252,258	-39,539 Reduced 78.33%	10,941 $19,000
Q2 2018 Aug 15, 2018	BUY	$3.29 - $4.82 $12,475 - $18,277	3,792 Added 8.12%	50,480 $0
Q1 2018 May 15, 2018	BUY	$1.81 - $5.98 $26,601 - $87,888	14,697 Added 45.94%	46,688 $0
Q4 2017 Feb 15, 2018	SELL	$1.8 - $2.32 $117,340 - $151,238	-65,189 Reduced 67.08%	31,991 $58,000
Q3 2017 Nov 14, 2017	SELL	$1.99 - $2.65 $28,395 - $37,812	-14,269 Reduced 12.8%	97,180 $212,000
Q2 2017 Aug 14, 2017	BUY	N/A	111,449	111,449 $309,000

Others Institutions Holding GERN

# of Institutions

275

Shares Held

491M

Call Options Held

1.87M

Put Options Held

690K

View Full List

About GERON CORP

Ticker GERN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 377,819,008
Market Cap $1.36B
Description
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hemat...

More about GERN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Metropolitan Life Insurance CO, based on Form 13F filings with the SEC.

News

Stay updated on Metropolitan Life Insurance CO with notifications on news.

Account